Patents by Inventor Mingshuo Zeng

Mingshuo Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOPENTYLPYRAZOLE CDK2 INHIBITORS
    Publication number: 20240425478
    Abstract: Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.
    Type: Application
    Filed: October 4, 2022
    Publication date: December 26, 2024
    Inventors: Jessica Marie GRANDNER, Kevin M. JOHNSON, Steven MAGNUSON, Jeremy Mark MURRAY, Brendan T. PARR, Vishal A. VERMA, Yong WANG, Mingshuo ZENG, Melissa A. ASHLEY
  • THERAPEUTIC COMPOUNDS
    Publication number: 20240383897
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Application
    Filed: March 13, 2024
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Elisia VILLEMURE, Joachim RUDOLPH, Mingshuo ZENG
  • ACYCLIC OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF
    Publication number: 20240228512
    Abstract: Provided herein are acyclic oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.
    Type: Application
    Filed: October 19, 2023
    Publication date: July 11, 2024
    Applicant: Genentech, Inc.
    Inventors: Benjamin David RAVETZ, Jack Alexander TERRETT, BinQing WEI, Mingshuo ZENG, Cheng SHAO, Yinlei SUN
  • Therapeutic compounds
    Patent number: 11993599
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: May 28, 2024
    Assignee: GENENTECH, INC.
    Inventors: Elisia Villemure, Joachim Rudolph, Mingshuo Zeng
  • THERAPEUTIC COMPOUNDS
    Publication number: 20230112485
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Application
    Filed: August 8, 2022
    Publication date: April 13, 2023
    Applicant: Genentech, Inc.
    Inventors: Elisia VILLEMURE, Joachim RUDOLPH, Mingshuo ZENG
  • New Pleuromutilin Antibiotic Compounds, Compositions and Methods of Use and Synthesis
    Publication number: 20190352262
    Abstract: The present invention is directed to novel pleuroniutilin antibiotic compounds, intermediates which are useful for making these novel amibioiic compounds and related methods and pharmaceutical compositions for treating pathogens, especially bacterial infections, including gram negative bacteria and synthesizing these compounds.
    Type: Application
    Filed: February 1, 2018
    Publication date: November 21, 2019
    Inventors: Seth Herzon, Stephen K. Murphy, Mingshuo Zeng